Neuronetics Inc. (STIM) on Tuesday shared that it will host virtual educational session and present clinical data about its NeuroStar Advanced Therapy treatment as part of a virtual program by the Clinical TMS Society.

Neuronetics is a commercial stage medical technology company which designs, develops and markets products for improved quality of life to patients suffering from psychiatric disorders.

The Clinical TMS Society is a professional association which focuses on accessibility and awareness about transcranial magnetic stimulation (TMS) therapy. The Society usually holds an Annual Meeting every year. But this year, instead of a traditional way, it is holding the virtual events to give the participants a chance to experience educational sessions remotely.

Neuronetics has been sponsoring the event by TCS and will also present a product theater webinar in that event. The company will also present two virtual posters bearing details of its latest research around NeuroStar Advanced Therapy for treatment of bipolar and unipolar depression. At the events, Neironetics is to present a product theater webinar on September, 29.

In the webinar, Neuronetics will address two topics including Treatment of Bipolar Depression: A Pilot Study; and Clinical Outcomes of NeuroStar Advanced Therapy Treatment: The Largest Patient Registry for Depression Treatment with Transcranial Magnetic Stimulation. Neuronetics’ two poster presentation will also be on display. Both posters will be displayed throughout the virtual poster session which will lasts till October 31.

One of company’s posters will present Comparison of Naturalistic Treatment Outcomes with the Standard 38-Minute Protocol vs. Shortened (“DASH”) Protocol: A NeuroStar Registry Database Study. Company’s analysis unveiled that efficacy of the DASH protocol at 19 minutes per session has been found constantly similar to the patients who went through the Standard treatment protocol of per session duration of 38 minutes.

While the other poster will present Post Marketing Rate of Seizures During Transcranial Magnetic Stimulation (TMS) Treatment with NeuroStar Advanced Therapy Is Low. An analysis which showed that seizures reported during TMS treatments with the NeuroStar Advanced Therapy device was even lower than previously estimated.